Founded in 2011 andheadquartered in Beijing Zhongguancun Biomedical Park, Beijing Advanced Medical Technologies, Ltd. Inc. (AMT) is a leading company in developing next generation of totally bioresorbable 3D printed vascular stents, including both coronary and peripheral stents. The core technology of the company is its proprietary 3D multi-axial printing technology. The company has built a strong patent portfolio around its core technology.

 

    The members of management team of AMT came from several international companies, such as Abbott Vascular, Celgene and St Jude, all with extensive experience in medical device R&D.

 

    AMT has received investment of several leading VC firms in China and also received several very competitive grants from both national and municipalgovernment funding agencies